Better Buy: Novavax, Inc. vs. Pfizer Inc.

Pfizer (NYSE: PFE) ranks as one of the giants of the pharmaceutical market, with a blockbuster vaccine franchise. Novavax (NASDAQ: NVAX) is only a fraction of Pfizer's size and is still at least a few years away from marketing its first vaccine -- if all goes well.

But size, and even revenue, doesn't necessarily make one stock better than another in the biopharmaceutical world. Instead, the potential for growth can make a small stock more attractive to investors than an established stock. So which of these two stocks is the better pick now? Here's how Novavax and Pfizer compare.

Image source: Getty Images.

Source: Fool.com